

United States Patent and Trademark Office



DATE MAILED: 03/27/2002

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/508,499	04/12/2000	ALAN FORBES MERRY	1115/0G778	1189
75	90 03/27/2002			
BERT J LEWEN DARBY & DARBY 805 THIRD AVENUE			EXAMINER	
			BARRETT, THOMAS C	
NEW YORK, NY 10022-7513			ART UNIT	PAPER NUMBER
			3738	

Please find below and/or attached an Office communication concerning this application or proceeding.

`		\mathcal{E}				
	Application No.	Applicant(s)				
	09/508,499	MERRY, ALAN FORBES				
Office Action Summary	Examiner	Art Unit				
	Thomas C. Barrett	3738				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) of ill apply and will expire SIX (6) MONTHS for cause the application to become ABANDO	timely filed days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 19 C	October 2001 .					
2a) This action is FINAL . 2b) ⊠ Thi	is action is non-final.					
3) Since this application is in condition for alloware closed in accordance with the practice under a Disposition of Claims						
4) Claim(s) 1-33,39 and 40 is/are pending in the	application.					
4a) Of the above claim(s) <u>12-25,27 and 29-33</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-11,26,28,39 and 40</u> is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120		() (I) == (D				
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119	9(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No3. Copies of the certified copies of the priority documents have been received in this National Stage						
3. Copies of the certified copies of the prior application from the International But* See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) The translation of the foreign language pro 15) Acknowledgment is made of a claim for domesti 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)				

DETAILED ACTION

Response to Arguments

Applicant's arguments with respect to claims 1-11, 26, 28 and 39-40 have been considered but are most in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-11, 26, 28, and 39-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Claeys et al. (4,853,521) as cited in Applicant's IDS. Claeys et al. discloses a method for verifying and administering drugs to a patient, wherein the first and second "coded sites" for a coded carrier (syringe) is determined by its arrangement (by order of use) on the tray (col. 2, lines 61- 63). The first and second "coded sites" do not have to be different "coded sites" because claim 39 claims them to be the same.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Application/Control Number: 09/508,499

Art Unit: 3738

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-11, 26, 28, and 39-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Claeys et al. (4,853,521) as cited in Applicant's IDS, in view of University of Maryland (News Article 10). Claeys et al. discloses a method for verifying and administering drugs to a patient, wherein the first "coded site" for a coded carrier (syringe) is determined by its arrangement (by order of use) on the tray (col. 2, lines 61-63), however fails to disclose a second coded substance site. University of Maryland teaches syringes (carrier) must be placed intact in a puncture proof sharps container that is labeled (a second coded substance site) with the words "SHARPS" or "BIOHAZARD" which prevents unacceptable risks to staff. It would have been obvious to one of ordinary skill in the art to combine the teaching of a second coded substance site in the form of a puncture proof sharps container, as taught by University of Maryland, to a method for verifying and administering drugs to a patient as per Claeys et al., in order to prevent unacceptable risks to staff.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas C. Barrett whose telephone number is (703) 308-8295. The examiner can normally be reached Tuesday-Friday between 9:00 A.M. and 6:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (703) 308-2111. The fax phone

Application/Control Number: 09/508,499

Art Unit: 3738

Page 4

numbers for the organization where this application or proceeding is assigned are (703) 305-3580 for regular communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308 0850.

Thomas Barrett March 21, 2002

> CORRINE McDERMOTT SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700